Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Helomics Continues Progress Toward AI-Driven Predictive Model of Ovarian Cancer
POAI’s Helomics division progresses toward critical milestone in CancerQuest2020 initiative Predictive models immensely valuable to pharmaceutical industry, improving drug evaluation without incurring high laboratory costs POAI is bringing precision medicine to the treatment of cancer for patients of today and tomorrow Predictive Oncology Inc. (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (AI) to personalized medicine and drug discovery, today announced continued progress by its Helomics subsidiary toward the goal of developing an AI-driven predictive model of ovarian cancer. This achievement will be a key milestone for the company’s CancerQuest2020 initiative (http://ibn.fm/mENY6). CancerQuest2020 is focused on building an AI-driven…